On December 30, 2005, NextGen Group Plc successfully completed its fundraising and admission to the AIM market of the London Stock Exchange, raising £2.4 million.
Nextgen is a provider of expert systems, services and reagents focused on enabling enhanced access to, and understanding of the role of, proteins in diagnosis and drug discovery. The money raised was required to commercialize its range of products and new drug discovery support services for the pharmaceutical and biotechnology industries.
David Smith, Nigel Gordon and Peter Rhodes of Fasken Martineau Stringer Saul LLP advised NextGen Group on this transaction.